RMDResmedQ3 FY2026Earnings Analysis

SolidFundamentals score7 / 10

How is this scored?

Base score5
Revenue up more than 5% YoY+1
Gross margin above 50%+1

Total7 / 10

Computed from published fixed rules, not a model's judgement — though one input, the count of high-severity risks, comes from the AI analysis below.

Not investment advice and not a price target: it scores the quarter's fundamentals, not the stock. Full methodology →

AI Takeaway

RMD reported strong financial performance in Q3 FY2026, with significant revenue growth and improved margins, driven by increased sales and effective cost management.

Revenue

$1.43B

+10.81% YoY

EPS (Diluted)

$2.74

+10.48% YoY

Gross Margin

62.2%

+2.9 pts YoY

Operating Income

$499.81M

+17.25% YoY

Filed May 1, 2026 · Analysis updated Jul 3, 2026 · Source: SEC EDGAR 10-Q filing

Next RMD earnings expected Oct 28, 2026

Revenue Growth, Margins & Profitability

Source: SEC XBRL

Resmed (RMD) reported Q3 FY2026 revenue of $1.43B, up 10.8% year over year. Operating margin was 34.9%, up 1.9 points from 33.0% a year earlier. RMD's fiscal Q3 FY2026 corresponds to calendar Q1 2026.

RMD vs Analyst Expectations

Last 4 quarters: 3 beats

Quarter	Actual EPS (USD)	Consensus (USD)	Result
Jun 2026	2.95	2.92	Beat +1.1%
Mar 2026This filing	2.86	2.82	Beat +1.3%
Dec 2025	2.81	2.75	Beat +2.1%
Sep 2025	2.55	2.58	Miss -1.2%

Adjusted (non-GAAP) EPS of $2.86 versus the $2.82 analyst consensus — a +1.3% beat for Mar 2026. Analyst consensus is quoted on the adjusted (non-GAAP) basis the street uses. GAAP diluted EPS for this quarter was $2.74.

RMD Q3 FY2026 Management Discussion Highlights

Compiled by AI from this SEC filing

Revenue Growth

RMD's revenue increased by 10.8% year-over-year, driven by strong sales performance across key markets.

Source: 10-Q Income Statement

Improved Gross Margin

Gross margin improved to 62.2%, reflecting better cost management and higher operational efficiency.

Source: 10-Q Income Statement

Increased R&D Investment

R&D expenses rose by 12.3%, indicating a focus on innovation and product development.

Source: 10-Q Income Statement

RMD Q3 FY2026 Risk Factors

Compiled by AI from this SEC filing · 1 high, 2 medium, 0 low

Supply Chain Disruptions

high

Potential disruptions in the supply chain could impact production and delivery schedules, affecting revenue and profitability.

Source: Industry Analysis

Currency Fluctuations

medium

Fluctuations in foreign exchange rates may adversely affect the company's international revenue and profitability.

Source: Industry Analysis

Regulatory Changes

medium

Changes in industry regulations could impose additional compliance costs and operational challenges.

Source: Industry Analysis

RMD Financial Charts & Detailed Metrics

Revenue & Net Income Trend

Margin Trend

View RMD's interactive chart on TradingViewLive price, indicators & drawing tools

Paid link→

Key Metrics

Income Statement

Metric	Current	Previous	YoY Change
Revenue $B	1.43 $B	1.29 $B	+10.81%
Cost of Revenue $M	540.43 $M	525.33 $M	+2.87%
Gross Profit $M	890.98 $M	766.41 $M	+16.25%
Operating Income $M	499.81 $M	426.27 $M	+17.25%
Net Income $M	398.73 $M	365.04 $M	+9.23%
EPS (Basic) $	2.74 $	2.49 $	+10.04%
EPS (Diluted) $	2.74 $	2.48 $	+10.48%
R&D Expense $M	94.27 $M	83.94 $M	+12.30%
SG&A Expense $M	285.66 $M	245.30 $M	+16.45%

Balance Sheet

Metric	Current	Previous	YoY Change
Total Assets $B	8.78 $B	7.57 $B	+16.09%
Current Assets $B	4.06 $B	3.21 $B	+26.67%
Total Liabilities $B	2.29 $B	2.02 $B	+13.45%
Current Liabilities $B	1.35 $B	0.94 $B	+43.67%
Stockholders' Equity $B	6.49 $B	5.55 $B	+17.05%
Cash & Equivalents $B	1.66 $B	0.93 $B	+78.03%
Long-Term Debt $M	404.17 $M	663.13 $M	-39.05%

Cash Flow

Metric	Current	Previous	YoY Change
Operating Cash Flow $BYTD	1.35 $B	1.21 $B	+11.41%
Investing Cash Flow $MYTD	-161.55 $M	-66.33 $M	-143.54%
Financing Cash Flow $MYTD	-743.87 $M	-442.37 $M	-68.16%
Dividends Paid $MYTD	262.57 $M	233.29 $M	+12.55%
Share Buybacks $MYTD	500.04 $M	200.02 $M	+150.00%
D&A $M	58.98 $M	43.68 $M	+35.05%

Key Ratios

Metric	Current	Previous	YoY Change
Gross Margin	62.2%	59.3%	+2.9 pts
Operating Margin	34.9%	33.0%	+1.9 pts
Net Margin	27.9%	—	—
ROE	6.1%	—	—
ROA	4.5%	—	—
Current Ratio	3.01	—	—
Debt to Equity	0.35	—	—

RMD Q3 FY2026 Earnings FAQ

Answers draw on this SEC filing and the data on this page

Did RMD beat earnings estimates in Q3 FY2026?

Adjusted (non-GAAP) EPS of $2.86 versus the $2.82 analyst consensus — a +1.3% beat for Q3 FY2026. Analyst consensus is quoted on the adjusted (non-GAAP) basis the street uses. GAAP diluted EPS for this quarter was $2.74.

What were the key takeaways from RMD Q3 FY2026 earnings?

Key takeaways include a 10.8% revenue growth, improved gross margin to 62.2%, and a significant increase in R&D investment by 12.3%.

How did RMD's revenue grow in Q3 FY2026?

RMD's revenue grew by 10.8% year-over-year to $1.43B, driven by strong sales across key markets.

What is RMD's current financial health?

RMD shows strong financial health with a current ratio of 3.01, indicating good liquidity, and a decrease in long-term debt by 39.1%.

What risks did RMD highlight in its Q3 FY2026 report?

Key risks include supply chain disruptions, currency fluctuations, and regulatory changes, which could impact operations and profitability.

When is the next RMD earnings date?

Resmed (RMD) is next expected to report earnings on Oct 28, 2026. The date comes from the analyst earnings calendar and can shift until the company confirms it.

Next RMD Earnings

RMD Q2 2026 Earnings Preview

Expected release date, analyst estimates & what to watch

More RMD Earnings Reports

RMD Q2 FY2026

RMD reported strong financial performance in Q2 FY2026 with significant growth in revenue and net income, driven by increased operational efficiency and robust market demand.

Related Earnings Analysis

Other companies in Health Care Equipment

Abbott Laboratories

Baxter International

Becton Dickinson

Boston Scientific

Dexcom

RMDResmedQ3 FY2026

SolidFundamentals score7 / 10

How is this scored?

Base score5
Revenue up more than 5% YoY+1
Gross margin above 50%+1

Total7 / 10

Computed from published fixed rules, not a model's judgement — though one input, the count of high-severity risks, comes from the AI analysis below.

Not investment advice and not a price target: it scores the quarter's fundamentals, not the stock. Full methodology →

AI Takeaway

RMD reported strong financial performance in Q3 FY2026, with significant revenue growth and improved margins, driven by increased sales and effective cost management.

Quarter

Actual EPS (USD)

Consensus (USD)

Result

Jun 2026

2.95

2.92

Beat +1.1%

Mar 2026This filing

2.86

2.82

Beat +1.3%

Dec 2025

2.81

2.75

Beat +2.1%

Sep 2025

2.55

2.58

Miss -1.2%

Metric

Current

YoY Change

Revenue $B

1.43

+10.81%

Cost of Revenue $M

540.43

+2.87%

Gross Profit $M

890.98

+16.25%

Operating Income $M

499.81

+17.25%

Net Income $M

398.73

+9.23%

EPS (Basic) $

2.74

+10.04%

EPS (Diluted) $

2.74

+10.48%

R&D Expense $M

94.27

+12.30%

SG&A Expense $M

285.66

+16.45%

Metric

Current

YoY Change

Total Assets $B

8.78

+16.09%

Current Assets $B

4.06

+26.67%

Total Liabilities $B

2.29

+13.45%

Current Liabilities $B

1.35

+43.67%

Stockholders' Equity $B

6.49

+17.05%

Cash & Equivalents $B

1.66

+78.03%

Long-Term Debt $M

404.17

-39.05%

Metric

Current

YoY Change

Operating Cash Flow $BYTD

1.35

+11.41%

Investing Cash Flow $MYTD

-161.55

-143.54%

Financing Cash Flow $MYTD

-743.87

-68.16%

Dividends Paid $MYTD

262.57

+12.55%

Share Buybacks $MYTD

500.04

+150.00%

D&A $M

58.98

+35.05%

Metric

Current

YoY Change

Gross Margin

62.2%

+2.9 pts

Operating Margin

34.9%

+1.9 pts

Net Margin

27.9%

—

ROE

6.1%

—

ROA

4.5%

—

Current Ratio

3.01

—

Debt to Equity

0.35

—